Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399124

2023-01-01

Abstract:XLSX file - 37K, Supplementary materials and methods (cell lines, STR profiles, primers, antibodies, molecular reagents).

What problem does this paper attempt to address?

Supplementary Table 2 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399139

2023-01-01

Abstract:XLSX file - 112K, GISTIC analysis of tumour samples.
Supplementary Table 1 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399142.v1

2023-01-01

Abstract:XLSX file - 37K, Details of the tumour samples use in the article.
Supplementary Table 6 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399127

2023-01-01

Abstract:XLSX file - 29K, Analysis of expression (cancer versus normal) and association with outcome for PSMB4 and SHMT2.
Supplementary Table 5 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399130

2023-01-01

Abstract:XLSX file - 39K, Gene copy number and ecpression (by Affymetrix and TaqMan) in cell lines used to screen for hits.
Supplementary Table 4 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399133

2023-01-01

Abstract:XLSX file - 65K, Gene Ontology analysis of gene over-expressed and amplified in the tumour samples.
Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528425

2023-01-01

Abstract:PDF file, 64K, Non-small cell lung cancer cell lines.
Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528419.v1

2023-01-01

Abstract:PDF file, 53K, mRNA transcripts significantly different between SCLC and NSCLC cell lines.
Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.
Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Humam Kadara,Li Shen,Junya Fujimoto,Pierre Saintigny,Chi-Wan Chow,Wenhua Lang,Zuoming Chu,Melinda Garcia,Mohamed Kabbout,You-Hong Fan,Carmen Behrens,Diane A. Liu,Li Mao,J. Jack Lee,Kathryn A. Gold,Jing Wang,Kevin R. Coombes,Edward S. Kim,Waun Ki Hong,Ignacio I. Wistuba

DOI: https://doi.org/10.1158/1940-6207.22524609.v1

2023-01-01

Abstract:XLSX file - 68K, Supplementary table depicting 1165 genes significantly differentially expressed by site in the molecular field of injury
Supplementary Table 2 from An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

Mark L. McCleland,Adam S. Adler,Yonglei Shang,Thomas Hunsaker,Tom Truong,David Peterson,Eric Torres,Li Li,Benjamin Haley,Jean-Philippe Stephan,Marcia Belvin,Georgia Hatzivassiliou,Elizabeth M. Blackwood,Laura Corson,Marie Evangelista,Jiping Zha,Ron Firestein

DOI: https://doi.org/10.1158/0008-5472.22394592

2023-01-01

Abstract:XLSX file - 59K, Genes that comprise the glycolysis and oxidative phosphorylation gene signatures
Supplementary Table 3 from An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

Mark L. McCleland,Adam S. Adler,Yonglei Shang,Thomas Hunsaker,Tom Truong,David Peterson,Eric Torres,Li Li,Benjamin Haley,Jean-Philippe Stephan,Marcia Belvin,Georgia Hatzivassiliou,Elizabeth M. Blackwood,Laura Corson,Marie Evangelista,Jiping Zha,Ron Firestein

DOI: https://doi.org/10.1158/0008-5472.22394589

2023-01-01

Abstract:XLSX file - 25K, RNAi optimization and screening conditions
Supplementary Table 1 from CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Liya Ding,Shuai Chen,Ping Liu,Yunqian Pan,Jian Zhong,Kevin M. Regan,Liguo Wang,Chunrong Yu,Anthony Rizzardi,Liang Cheng,Jun Zhang,Stephen C. Schmechel,John C. Cheville,Jan Van Deursen,Donald J. Tindall,Haojie Huang

DOI: https://doi.org/10.1158/0008-5472.22401353.v1

2023-01-01

Abstract:XLSX file - 9KB, Supplemental Table S1. Primers for genotyping, RT-qPCR and ChIP-qPCR.
Supplementary Table 1 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Hong Ren,Zhi-Ping Tan,Xin Zhu,Katherine Crosby,Herbert Haack,Jian-Min Ren,Sean Beausoleil,Albrecht Moritz,Gregory Innocenti,John Rush,Yi Zhang,Xin-Min Zhou,Ting-Lei Gu,Yi-Feng Yang,Michael J. Comb

DOI: https://doi.org/10.1158/0008-5472.22389582.v1

2023-01-01

Abstract:XLS file - 31K, Patient Diagnostic Information
Supplementary Table 1 from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets

Barbara Stefanska,David Cheishvili,Matthew Suderman,Ani Arakelian,Jian Huang,Michael Hallett,Ze-Guang Han,Mamun Al-Mahtab,Sheikh Mohammad Fazle Akbar,Wasif Ali Khan,Rubhana Raqib,Imrana Tanvir,Haseeb Ahmed Khan,Shafaat A. Rabbani,Moshe Szyf

DOI: https://doi.org/10.1158/1078-0432.22452299.v1

2023-01-01

Abstract:XLS file - 32KB, Supplementary Table S1. List of siRNAs, shRNAs, primer sequences used in expression analysis (QPCR) and pyrosequencing.
Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Martin H. Voss,A. Ari Hakimi,Can G. Pham,A. Rose Brannon,Ying-Bei Chen,Luı́s Cunha,Oğuz Akın,Han Liu,Shugaku Takeda,Sasinya N. Scott,Nicholas D. Socci,Agnès Viale,Nikolaus Schultz,Chris Sander,Victor E. Reuter,Paul Russo,Emily H. Cheng,Robert J. Motzer,Michael F. Berger,James J. Hsieh

DOI: https://doi.org/10.1158/1078-0432.22450608.v1

2023-01-01

Abstract:XLSX file - 910K, Supplementary Table S4. Impact assay exon coverage on all samples.
Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Junfeng Xia,Peilin Jia,Katherine E. Hutchinson,Kimberly B. Dahlman,Douglas Johnson,Jeffrey Sosman,William Pao,Zhongming Zhao

DOI: https://doi.org/10.1158/1535-7163.22500162

2023-01-01

Abstract:XLSX - 28K, Supplementary Table S14. Mutations in 12 potential cancer genes in pan-negative melanoma samples.
Supplementary Data from Array-Based Comparative Genomic Hybridization Identifies cdk4 and foxm1 Alterations As Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor

Jin‐Sheng Yu,Hrishikesh Deshmukh,Jacqueline E. Payton,Christopher Dunham,Bernd W. Scheithauer,Tarık Tihan,Richard A. Prayson,Abhijit Guha,Julia A. Bridge,R E Ferner,Guy Lindberg,Rebecca J. Gutmann,Ryan J. Emnett,Lorena Salavaggione,David H. Gutmann,Rakesh Nagarajan,Mark A. Watson,Arie Perry

DOI: https://doi.org/10.1158/1078-0432.22442091.v1

2023-01-01

Abstract:Supplementary Materials and Methods; Supplementary Tables S1-S5.
Supplementary Table 3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Hong Ren,Zhi-Ping Tan,Xin Zhu,Katherine Crosby,Herbert Haack,Jian-Min Ren,Sean Beausoleil,Albrecht Moritz,Gregory Innocenti,John Rush,Yi Zhang,Xin-Min Zhou,Ting-Lei Gu,Yi-Feng Yang,Michael J. Comb

DOI: https://doi.org/10.1158/0008-5472.22389576.v1

2023-01-01

Abstract:XLS file - 40K, Abundance of phospho-peptides corresponding to specific signaling molecules in selective serous carcinoma patients
Supplementary Table 1 from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Adam J. MacNeil,Shun-Chang Jiao,Lori A. McEachern,Yong Jun Yang,Amanda Dennis,Haiming Yu,Zhaolin Xu,Jean S. Marshall,Tong-Jun Lin

DOI: https://doi.org/10.1158/0008-5472.22399527

2023-01-01

Abstract:XLSX file - 27K, Supplementary Table S1. Clinical grading and tumour marker profile information.

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 2 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 1 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 6 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 5 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 4 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Table 2 from An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

Supplementary Table 3 from An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

Supplementary Table 1 from CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Supplementary Table 1 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Table 1 from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets

Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Supplementary Data from Array-Based Comparative Genomic Hybridization Identifies &lt;i&gt;cdk4&lt;/i&gt; and &lt;i&gt;foxm1&lt;/i&gt; Alterations As Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor

Supplementary Table 3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Table 1 from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Supplementary Data from Array-Based Comparative Genomic Hybridization Identifies <i>cdk4</i> and <i>foxm1</i> Alterations As Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor